A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation

Oncotarget

Volumn 6, Issue 30, 2015, Pages 29347-29356

  Artemov, Artem ^a,b   Aliper, Alexander ^b,c   Korzinkin, Michael ^a   Lezhnina, Ksenia ^a   Jellen, Leslie ^d   Zhukov, Nikolay ^b,c,e   Roumiantsev, Sergey ^b,e   Gaifullin, Nurshat ^f   Zhavoronkov, Alex ^g   Borisov, Nicolas ^c   Buzdin, Anton ^a,b,h  

^a Pathway Pharmaceuticals Limited   (Hong Kong)

^b Clinical Center of Pediatric Hematology Oncology and Immunology   (Russian Federation)

^c First Oncology Research and Advisory Center   (Russian Federation)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^f MOSCOW STATE UNIVERSITY   (Russian Federation)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

Bioinformatic modeling; Cancer; Intracellular signaling pathway; Personalized medicine; Response to target drug therapy

Indexed keywords

BEVACIZUMAB; CETUXIMAB; IMATINIB; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ALGORITHM; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COLON CANCER; DRUG EFFICACY; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL ANALYSIS; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; PREDICTION; SARCOMA; SCORING SYSTEM; SIGNAL TRANSDUCTION; THYROID CANCER; TUMOR PROMOTION; ANTAGONISTS AND INHIBITORS; BIOLOGY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DRUG DISCOVERY; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATIENT SELECTION; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION;

EID: 84945144277     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5119     Document Type: Article

References (49)

1. Hanna N, Einhorn LH: Testicular cancer: a reflection on 50 years of discovery. J Clin Oncol Off J Am Soc Clin Oncol 2014, 32:3085-3092.
2. Oldenburg J, Aparicio J, Beyer J, Cohn-Cedermark G, Cullen M, Gilligan T, De Giorgi U, De Santis M, de Wit R, Fosså SD, Germà-Lluch JR, Gillessen S, Haugnes HS, Honecker F, Horwich A, Lorch A, Ondruš D, Rosti G, Stephenson AJ, Tandstad T, On behalf of: SWENOTECA (Swedish Norwegian Testicular Cancer group), the Italian Germ Cell Cancer Group (IGG), Spanish Germ Cell Cancer Group (SGCCG): Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO 2014.
3. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Titus-Ernstoff L, Skalla K, Bakitas M, Silberfarb PM: Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. J Clin Oncol Off J Am Soc Clin Oncol 2005, 23:4399-4405.
4. Kayl AE, Meyers CA: Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr Opin Obstet Gynecol 2006, 18:24-28.
5. Zhukov NV, Tjulandin SA: Targeted therapy in the treatment of solid tumors: practice contradicts theory. Biochem Biokhimiia 2008, 73:605-618.
6. Sjöström J: Predictive factors for response to chemotherapy in advanced breast cancer. Acta Oncol Stockh Swed 2002, 41:334-345.
7. Sawyers C: Targeted cancer therapy. Nature 2004, 432:294-297.
8. Aggarwal S: Targeted cancer therapies. Nat Rev Drug Discov 2010, 9:427-428.
9. Hudis CA: Trastuzumab-Mechanism of Action and Use in Clinical Practice. N Engl J Med 2007, 357:39-51.
10. Nahta R, Esteva FJ: Trastuzumab: triumphs and tribulations. Oncogene 2007, 26:3637-3643.
11. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009, 7:4-13.
12. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AMM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
13. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ: CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res Off J Am Assoc Cancer Res 2012, 18:2039-2047.
14. Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T: Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer Amst Neth 2011, 71:249-257.
15. Grothey A, Lenz H-J: Explaining the unexplainable: EGFR antibodies in colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 2012, 30:1735-1737.
16. Hornberger J, Cosler LE, Lyman GH: Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, earlystage breast cancer. Am J Manag Care 2005, 11:313-324.
17. Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, Mauborgne C, Rouleau E, Reyes C, Henry E, Leroy Q, Gestraud P, La Rosa P, Escalup L, Mitry E, Trédan O, Delord J-P, Campone M, Goncalves A, Isambert N, et al.: Randomised proof-of-concept phase II trial comparing targeted therapy based on tumor molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br J Cancer 2014, 111:17-24.
18. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038-1042.
19. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, OhnoJones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
20. Khatri P, Sirota M, Butte AJ: Ten Years of Pathway Analysis: Current Approaches and Outstanding Challenges. PLoS Comput Biol 2012, 8:e1002375.
21. Khatri P, Draghici S: Ontological analysis of gene expression data: current tools, limitations, and open problems. Bioinforma Oxf Engl 2005, 21:3587-3595.
22. Khatri P, Draghici S, Ostermeier GC, Krawetz SA: Profiling Gene Expression Using Onto-Express. Genomics 2002, 79:266-270.
23. Zeeberg BR, Feng W, Wang G, Wang MD, Fojo AT, Sunshine M, Narasimhan S, Kane DW, Reinhold WC, Lababidi S, Bussey KJ, Riss J, Barrett JC, Weinstein JN: GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol 2003, 4:R28.
24. Barry WT, Nobel AB, Wright FA: Significance analysis of functional categories in gene expression studies: a structured permutation approach. Bioinforma Oxf Engl 2005, 21:1943-1949.
25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genomewide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
26. Tian L, Greenberg SA, Kong SW, Altschuler J, Kohane IS, Park PJ: Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci U S A 2005, 102:13544-13549.
27. Mitrea C, Taghavi Z, Bokanizad B, Hanoudi S, Tagett R, Donato M, Voichita C, Draghici S: Methods and approaches in the topology-based analysis of biological pathways. Front Physiol 2013, 4.
28. Afsari B, Geman D, Fertig EJ: Learning dysregulated pathways in cancers from differential variability analysis. Cancer Inform 2014, 13(Suppl 5):61-67.
29. Ho JWK, Stefani M, dos Remedios CG, Charleston MA: Differential variability analysis of gene expression and its application to human diseases. Bioinforma Oxf Engl 2008, 24:i390-398.
30. Eddy JA, Hood L, Price ND, Geman D: Identifying tightly regulated and variably expressed networks by Differential Rank Conservation (DIRAC). PLoS Comput Biol 2010, 6:e1000792.
31. Zhang J, Li J, Deng H-W: Identifying gene interaction enrichment for gene expression data. PloS One 2009, 4:e8064.
32. Buzdin AA, Zhavoronkov AA, Korzinkin MB, Venkova LS, Zenin AA, Smirnov PY, Borisov NM: Oncofinder, a new method for the analysis of intracellular signaling pathway activation using transcriptomic data. Front Genet 2014, 5:55.
33. Buzdin AA, Zhavoronkov AA, Korzinkin MB, Roumiantsev SA, Aliper AM, Venkova LS, Smirnov PY, Borisov NM: The OncoFinder algorithm for minimizing the errors introduced by the high-throughput methods of transcriptome analysis. Mol Diagn 2014, 1:8.
34. Borisov NM, Terekhanova NV, Aliper AM, Venkova LS, Smirnov PY, Roumiantsev S, Korzinkin MB, Zhavoronkov AA, Buzdin AA: Signaling pathway activation profiles make better markers of cancer than expression of individual genes. Oncotarget 2014, Aug 23. PMID: 25337906.
35. Lezhnina K, Kovalchuk O, Zhavoronkov AA, Korzinkin MB, Zabolotneva AA, Shegay PV, Sokov DG, Gaifullin NM, Rusakov IG, Aliper AM, Roumiantsev SA, Alekseev BY, Borisov NM, Buzdin AA: Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways. Oncotarget 2014, 5:9022-9032.
36. Spirin PV, Lebedev TD, Orlova NN, Gornostaeva AS, Prokofjeva MM, Nikitenko NA, Dmitriev SE, Buzdin AA, Borisov NM, Aliper AM, Garazha AV, Rubtsov PM, Stocking C, Prassolov VS: Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling. Leukemia 2014, 28:2222-2228.
37. Zhu Q, Izumchenko E, Aliper AM, Makarev E, Paz K, Buzdin AA, Zhavoronkov AA, Sidransky D: Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients. Hum Genome Var 2015, 2:15009.
38. Aliper AM, Csoka AB, Buzdin A, Jetka T, Roumiantsev S, Moskalev A, Zhavoronkov A: Signaling pathway activation drift during aging: Hutchinson-Gilford Progeria Syndrome fibroblasts are comparable to normal middle-age and oldage cells. Aging 2015, 7:26-37.
39. Makarev E, Cantor C, Zhavoronkov A, Buzdin A, Aliper A, Csoka AB: Pathway activation profiling reveals new insights into age-related macular degeneration and provides avenues for therapeutic interventions. Aging 2014, 6:1064-1075.
40. Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther 2006, 28:461-474.
41. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, AFFIRM Investigators: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
42. Compston A, Coles A: Multiple sclerosis. Lancet 2008, 372:1502-1517.
43. Contino-Pépin C, Parat A, Périno S, Lenoir C, Vidal M, Galons H, Karlik S, Pucci B: Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application. Bioorg Med Chem Lett 2009, 19:878-881.
44. Sastry PS: Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis. Med Hypotheses 1999, 53:76-77.
45. Azizi G, Goudarzvand M, Afraei S, Sedaghat R, Mirshafiey A: Therapeutic effects of dasatinib in mouse model of multiple sclerosis. Immunopharmacol Immunotoxicol 2015:1-8.
46. Gordon JK, Spiera RF: Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis. Curr Opin Rheumatol 2010, 22:690-695.
47. O'Sullivan D, Miller JH, Northcote PT, La Flamme AC: Microtubule-stabilizing agents delay the onset of EAE through inhibition of migration. Immunol Cell Biol 2013, 91:583-592.
48. Reva B, Antipin Y, Sander C: Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 2011, 39:e118.
49. Gautier L, Cope L, Bolstad BM, Irizarry RA: affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20:307-315.